Impact of anxio-depressive symptoms and cognitive function on oral anticancer therapies adherence
- 28 January 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 27 (9), 3573-3581
- https://doi.org/10.1007/s00520-019-4644-4
Abstract
Oral anticancer therapies have an important place in the therapeutic arsenal, but factors influencing adherence to oral treatment are poorly documented in oncology. The objective of this study was to assess the impact of anxio-depressive symptoms and cognitive functioning on oral medication adherence.Keywords
This publication has 31 references indexed in Scilit:
- Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric studyAnnals Of Oncology, 2013
- Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancerBreast Cancer Research and Treatment, 2010
- The impact of cognitive function on medication management: Three studies.Health Psychology, 2010
- Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare CostsPharmacoEconomics, 2007
- Adherence to MedicationThe New England Journal of Medicine, 2005
- Medication adherence in HIV-infected adultsAIDS, 2004
- A Changing Paradigm for Cancer Treatment: The Advent of New Oral Chemotherapy AgentsClinical Journal of Oncology Nursing, 2003
- Oral cancer treatment: developments in chemotherapy and beyondBritish Journal of Cancer, 2002
- The CES-D ScaleApplied Psychological Measurement, 1977
- Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily LivingThe Gerontologist, 1969